We are a clinical-stage biotechnology company focused on restoring function by developing therapeutics that activate a person’s innate regenerative potential.
Frequency is leading a new category in regenerative medicine designed to activate a person’s innate regenerative potential, within the body, to repair tissue and restore function.
Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases
Hearing loss caused by damage to the sensory cells of the ear impacts hundreds of millions of people globally. Currently there are no FDA-approved treatments to address the underlying condition.
Institute Professor, Massachusetts Institute of Technology
Harvard Medical School; Brigham & Women's Hospital
Harvard Medical School; Broad Institute of MIT & Harvard
Harvard Medical School; Center for Systems Biology at MGH.
Scripps Research Center
Harvard Medical School; Boston Children’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School; Brigham & Women’s Hospital
PureTech Health; Former President of R&D, Pfizer
UT Southwestern; Howard Hughes Medical Institute
Columbia University
Harvard University; Joslin Diabetes Center
Wellcome Trust-MRC Cambridge Stem Cell Institute; MS Society Cambridge Centre for Myelin Repair
Gladstone Institute of Cardiovascular Disease; University of California San Francisco
